{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:41:13Z","timestamp":1792075273511,"version":"4.4.0"},"reference-count":59,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Many biologic therapies are available for moderate\u2010to\u2010severe plaque psoriasis. A systematic literature review and network meta\u2010analysis (NMA) was conducted to compare the efficacy of the interleukin\u00a0(IL)\u201023\u00a0inhibitor, tildrakizumab, with other biologics at up to 28\u2009weeks of treatment. The literature search was conducted on January 22, 2024, searching MEDLINE, Embase, and CENTRAL for randomized controlled trials (RCTs) investigating the comparative efficacy and safety of biologics in adult Asian patients with moderate\u2010to\u2010severe plaque psoriasis. NMAs were conducted for \u2265\u200975%, \u2265\u200990%, and 100% reduction in Psoriasis Area and Severity Index score (PASI 75, 90, and 100) and achieving a Physician Global Assessment (PGA) score of 0 or 1 after the induction period (12 and 16\u2009weeks) and mid\u2010term (28\u2009weeks) follow\u2010up. NMAs were conducted using the Bayesian framework outlined in the National Institute of Clinical Excellence guidelines. Nineteen RCTs conducted in China, Japan, Korea, and Taiwan with 11 different biologics were included. At Week 12, tildrakizumab had lower efficacy compared to other biologics. Between Weeks 12 and 28, the proportion of patients achieving PASI 75\/90\/100 with tildrakizumab increased from 60.77% to 81.84%, from 38.54% to 71.23%, and from 6.97% to 22.64%, respectively. At Week 28, tildrakizumab efficacy was comparable to other biologic therapies studied here, including tumor necrosis factor\u2010alpha (TNF\u03b1), IL\u201017, IL\u201012\/IL\u201023, and other IL\u201023 inhibitors. The efficacy of tildrakizumab improved over time, which underscores the importance of evaluating the sustained efficacy of tildrakizumab over the long term. Combined with low dosing frequency, tildrakizumab offers an effective treatment option for patients with moderate\u2010to\u2010severe plaque psoriasis.<\/jats:p>","DOI":"10.1111\/ijd.70092","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T15:39:01Z","timestamp":1760974741000},"page":"505-515","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy of Biologics for the Treatment of Moderate\u2010To\u2010Severe Plaque Psoriasis in the Asian Population: A Systematic Review and Network Meta\u2010Analysis"],"prefix":"10.1111","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6127-3182","authenticated-orcid":false,"given":"Akihiko","family":"Asahina","sequence":"first","affiliation":[{"name":"The Jikei University School of Medicine  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-3848","authenticated-orcid":false,"given":"Mir Sohail","family":"Fazeli","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6331-5497","authenticated-orcid":false,"given":"Robyn","family":"Kendall","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2671-9331","authenticated-orcid":false,"given":"Gopika","family":"Balasubramanian","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9773-5837","authenticated-orcid":false,"given":"Paul","family":"Serafini","sequence":"additional","affiliation":[{"name":"Evidinno Outcomes Research Inc  Vancouver Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif","family":"Shaikh","sequence":"additional","affiliation":[{"name":"Sun Pharmaceutical Industries, Inc.  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9140-9196","authenticated-orcid":false,"given":"Ranga","family":"Gogineni","sequence":"additional","affiliation":[{"name":"Sun Pharmaceutical Industries, Inc.  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5485-682X","authenticated-orcid":false,"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05663"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3386"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.02.003"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.055"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02065-w"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2019.4029"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220868"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17448"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00843-6"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1432"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12458724"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6475"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9868.00353"},{"key":"e_1_2_10_16_1","unstructured":"\u201cHUMIRA (Adalimumab) Prescribing Information \u201d(2021) http:\/\/www.rxabbvie.com\/pdf\/humira.pdf."},{"key":"e_1_2_10_17_1","unstructured":"\u201cCIMZIA (Cetrolizumab Pegol) Prescribing Information \u201d(2024) https:\/\/www.cimziahcp.com\/full\u2010prescribing\u2010info."},{"key":"e_1_2_10_18_1","unstructured":"\u201cRemicade (Infliximab) Prescribing Information \u201d(2021) https:\/\/www.janssenlabels.com\/package\u2010insert\/product\u2010monograph\/prescribing\u2010information\/REMICADE\u2010pi.pdf."},{"key":"e_1_2_10_19_1","unstructured":"\u201cBimzelx (Bimekizumab) Prescribing Information \u201d(2024) https:\/\/www.bimzelxhcp.com\/prescribing\u2010information.pdf?_gl=1%2Athjj0v%2A_ga%2ANDUxMjQ1OTQ3LjE3Mjk2Njc5MjA.%2A_ga_CKX2D73W9W%2AMTczMTQwMjY0Ni41MS4xLjE3MzE0MDQ3MTguMC4wLjA."},{"key":"e_1_2_10_20_1","unstructured":"\u201cSILIQ (Brodalumab) Prescribing Information \u201d(2024) https:\/\/www.bauschhealth.com\/Portals\/25\/Pdf\/PI\/Siliq\u2010pi.pdf."},{"key":"e_1_2_10_21_1","unstructured":"\u201cTALTZ (Ixekizumab) Prescribing Information \u201d(2024) http:\/\/uspl.lilly.com\/taltz\/taltz.html?s=pi."},{"key":"e_1_2_10_22_1","unstructured":"\u201cCosentyx (Secukinumab) Prescribing Information \u201d(2024) https:\/\/www.novartis.com\/us\u2010en\/sites\/novartis_us\/files\/cosentyx.pdf."},{"key":"e_1_2_10_23_1","unstructured":"\u201cTremfya (Guselkumab) Prescribing Information \u201d(2024) https:\/\/www.janssenlabels.com\/package\u2010insert\/product\u2010monograph\/prescribing\u2010information\/TREMFYA\u2010pi.pdf."},{"key":"e_1_2_10_24_1","unstructured":"\u201cSkyrizi (Risankizumab) Prescribing Information \u201d(2024) https:\/\/www.rxabbvie.com\/pdf\/skyrizi_pi.pdf."},{"key":"e_1_2_10_25_1","unstructured":"\u201cILUMYA (Tildrakizumab) Prescribing Information \u201d(2022) https:\/\/www.ilumya.com\/Sun_Pharma_ILUMYA_US_Prescribing_Information_.pdf."},{"key":"e_1_2_10_26_1","unstructured":"\u201cStelara (Ustekinumab) Prescribing Information \u201d(2019) https:\/\/www.janssenlabels.com\/package\u2010insert\/product\u2010monograph\/prescribing\u2010information\/STELARA\u2010pi.pdf."},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2009.00748.x"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13746"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00520-0"},{"key":"e_1_2_10_30_1","unstructured":"Clinicaltrials.gov \u201cNCT03051217. A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis \u201dhttps:\/\/clinicaltrials.gov\/study\/NCT03051217."},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2010.04.014"},{"issue":"11","key":"e_1_2_10_32_1","first-page":"1845","article-title":"Infliximab Monotherapy for Chinese Patients With Moderate to Severe Plaque Psoriasis: A Randomized, Double\u2010Blind, Placebo\u2010Controlled Multicenter Trial","volume":"125","author":"Yang H. Z.","year":"2012","journal-title":"Chinese Medical Journal"},{"key":"e_1_2_10_33_1","unstructured":"Clinicaltrials.gov \u201cNCT01177800. A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque\u2010Type Psoriasis \u201d(2025) https:\/\/clinicaltrials.gov\/study\/NCT01177800."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00883-y"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2015.10.009"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15733"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13927"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/JD9.0000000000000244"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12668"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13900"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001163"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14504"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14941"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15789"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002873"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2011.05.005"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01347.x"},{"issue":"2","key":"e_1_2_10_48_1","first-page":"166","article-title":"Efficacy and Safety of Ustekinumab in Chinese Patients With Moderate to Severe Plaque\u2010Type Psoriasis: Results From a Phase 3 Clinical Trial (LOTUS)","volume":"12","author":"Zhu X.","year":"2013","journal-title":"Journal of Drugs in Dermatology"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19866"},{"key":"e_1_2_10_51_1","article-title":"Treatment of Moderate\u2010To\u2010Severe Plaque Psoriasis With Tildrakizumab in the Real\u2010Life Setting","volume":"10","author":"Burlando M.","year":"2021","journal-title":"Drugs in Context"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19229"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15763"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.017"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.042"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31713-6"},{"issue":"7","key":"e_1_2_10_58_1","article-title":"Systemic Pharmacological Treatments for Chronic Plaque Psoriasis: A Network Meta\u2010Analysis","volume":"7","author":"Sbidian E.","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01423-0"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2024.100261"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70092","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.70092","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.70092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T09:51:53Z","timestamp":1772963513000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.70092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1111\/ijd.70092"],"URL":"https:\/\/doi.org\/10.1111\/ijd.70092","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"2025-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}